A randomized phase II efficacy and correlative studies of cetuximab with or without sorafenib in recurrent and/or metastatic head and neck squamous cell carcinoma.

Gilbert J, Schell MJ, Zhao X, Murphy B, Tanvetyanon T, Leon ME, Neil Hayes D, Haigentz M, Saba N, Nieva J, Bishop J, Sidransky D, Ravi R, Bedi A, Chung CH
Oral Oncol. 2015 51 (4): 376-82

PMID: 25593015 · PMCID: PMC4459134 · DOI:10.1016/j.oraloncology.2014.12.011

MeSH Terms (15)

Adult Aged Antineoplastic Agents Carcinoma, Squamous Cell Cetuximab Female Head and Neck Neoplasms Humans Male Middle Aged Neoplasm Metastasis Niacinamide Phenylurea Compounds Recurrence Sorafenib

Connections (1)

This publication is referenced by other Labnodes entities: